Market capitalization | CHF204.77b |
Enterprise Value | CHF234.34b |
P/E (TTM) P/E ratio | 19.29 |
EV/FCF (TTM) EV/FCF | 20.06 |
EV/Sales (TTM) EV/Sales | 3.99 |
P/S ratio (TTM) P/S ratio | 3.48 |
P/B ratio (TTM) P/B ratio | 7.08 |
Dividend yield | 3.74% |
Last dividend (FY23) | CHF9.60 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
22 Analysts have issued a Roche forecast:
22 Analysts have issued a Roche forecast:
Jun '24 |
+/-
%
|
||
Revenue | 58,785 58,785 |
3%
3%
|
|
Gross Profit | 42,873 42,873 |
3%
3%
|
|
EBITDA | 19,842 19,842 |
6%
6%
|
EBIT (Operating Income) EBIT | 16,464 16,464 |
5%
5%
|
Net Profit | 10,619 10,619 |
4%
4%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Thomas Schinecker |
Employees | 103,605 |
Founded | 1896 |
Website | www.roche.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.